November 30, 2016 - By Marguerite Chambers
An insider of the company Quidel Corp, John Tamerius also its SVP – Strat & Ext Affairs, disclosed his trading activities with the Security and Exchange Commission on 29/11/2016. As announced in the document, John had sold 8,878 shares of the company. The total insider transaction was worth $208,633 U.S Dollars. At the time of the sale the price of a share was $23.5. John Tamerius currently owns 23,540 shares or 0.07% of Quidel Corp’s market cap.
Out of 4 analysts covering Quidel (NASDAQ:QDEL), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. $28.0 is the highest target while $16 is the lowest. The $19.25 average target is -14.94% below today’s ($22.63) stock price. Quidel has been the topic of 10 analyst reports since September 2, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Tuesday, February 9 by Canaccord Genuity. Craig Hallum downgraded Quidel Corporation (NASDAQ:QDEL) on Friday, October 23 to “Hold” rating. Barclays Capital initiated Quidel Corporation (NASDAQ:QDEL) rating on Wednesday, September 2. Barclays Capital has “Overweight” rating and $28.0 price target. Raymond James downgraded Quidel Corporation (NASDAQ:QDEL) on Monday, December 14 to “Mkt Perform” rating. The company was upgraded on Monday, June 13 by Raymond James. The firm earned “Buy” rating on Friday, January 8 by Canaccord Genuity.
Insitutional Activity: The institutional sentiment increased to 1.11 in Q2 2016. Its up 0.30, from 0.81 in 2016Q1. The ratio improved, as 8 funds sold all Quidel Corporation shares owned while 34 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 30.18 million shares or 0.20% less from 30.24 million shares in 2016Q1.
Citigroup Inc holds 0% of its portfolio in Quidel Corporation (NASDAQ:QDEL) for 2,406 shares. Moreover, Tower Research Cap Ltd Llc (Trc) has 0% invested in Quidel Corporation (NASDAQ:QDEL) for 1,568 shares. Wall Street Assoc accumulated 157,578 shares or 1.13% of the stock. Ig Management Limited reported 61,533 shares or 0% of all its holdings. Swiss Comml Bank last reported 48,300 shares in the company. Brown Capital Mgmt Ltd Liability Company holds 1.62% of its portfolio in Quidel Corporation (NASDAQ:QDEL) for 5.75 million shares. Manufacturers Life Insurance The last reported 19,216 shares in the company. State Board Of Administration Of Florida Retirement System last reported 0% of its portfolio in the stock. Pitcairn accumulated 0.04% or 17,593 shares. Blackrock accumulated 0% or 22,726 shares. Menta Cap Limited Co has invested 0.09% of its portfolio in Quidel Corporation (NASDAQ:QDEL). Invest Mgmt Of Virginia Ltd Liability has 1.86% invested in the company for 407,667 shares. Eagle Boston Inv Mngmt has 326,489 shares for 0.79% of their US portfolio. Financial Bank Of Mellon Corp owns 215,223 shares or 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 1,579 shares.
Insider Transactions: Since August 1, 2016, the stock had 0 insider buys, and 4 sales for $2.23 million net activity. On Tuesday, August 30 the insider BRYANT DOUGLAS C sold $62,304. $498,012 worth of Quidel Corporation (NASDAQ:QDEL) was sold by Bujarski Robert Joseph on Friday, August 5. 7,000 shares with value of $161,124 were sold by TAMERIUS JOHN on Monday, August 1.
The stock decreased 1.05% or $0.24 on November 29, hitting $22.63. About 101,852 shares traded hands. Quidel Corporation (NASDAQ:QDEL) has risen 17.28% since April 26, 2016 and is uptrending. It has outperformed by 12.02% the S&P500.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The company has a market cap of $718.00 million. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It currently has negative earnings. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers.
According to Zacks Investment Research, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis.”
Analysts await Quidel Corporation (NASDAQ:QDEL) to report earnings on February, 15. They expect $0.22 earnings per share, up 214.29% or $0.15 from last year’s $0.07 per share. QDEL’s profit will be $6.98M for 25.72 P/E if the $0.22 EPS becomes a reality. After $0.04 actual earnings per share reported by Quidel Corporation for the previous quarter, Wall Street now forecasts 450.00% EPS growth.
More recent Quidel Corporation (NASDAQ:QDEL) news were published by: Streetinsider.com which released: “Quidel Corp (QDEL) Granted FDA 510(k) Clearance for New Solana Molecular Assay” on November 29, 2016. Also Marketwatch.com published the news titled: “Quidel upgraded to outperform from market perform at Raymond James” on December 21, 2009. Seekingalpha.com‘s news article titled: “Quidel Corporation’s (QDEL) CEO Doug Bryant on Q3 2016 Results – Earnings Call ..” with publication date: October 27, 2016 was also an interesting one.
Quidel Corporation, incorporated on July 14, 1987, is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. The Firm sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. The Company’s diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including infectious diseases, women’s health, autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.